Salicylate (Salsalate) in patients with type 2 diabetes: A randomized trial

Annals of Internal Medicine

Volumn 159, Issue 1, 2013, Pages 1-12

  Goldfine, Allison B ^a   Fonseca, Vivian ^b   Jablonski, Kathleen A ^c   Chen, Yii Der Ida ^d   Tipton, Laura ^c   Staten, Myrlene A ^e   Shoelson, Steven E ^a  

^a JOSLIN DIABETES CENTER   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALBUMIN; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SALICYLIC ACID; SALSALATE; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMATOCRIT; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL COUNT; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SIDE EFFECT; SINGLE BLIND PROCEDURE; TINNITUS; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MIDDLE AGED; SALICYLATES; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84879564109     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-1-201307020-00003     Document Type: Article

References (53)

1. Jack DB. One hundred years of aspirin. Lancet. 1997;350:437-9. [PMID: 9259670]
2. MacLagan TJ. The treatment of acute rheumatism by salicin. Lancet. 1876; 107:342-3, 383-4.
3. Broadbent WH. Treatment of rheumatic fever by salicylic acid. Lancet. 1876; 107:530-2.
4. Mann CC, Plummer ML. The Aspirin Wars: Money, Medicine and 100 Years of Rampant Competition. Boston: Harvard Business School Pr; 1991.
5. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol. 1995;2:637-43. [PMID: 7552725]
6. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001;293:1673-7. [PMID: 11533494]
7. Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008;1:36-43. [PMID: 19337387]
8. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE; TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010;152:346-57. [PMID: 20231565]
9. Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 2011. [PMID: 21938543]
10. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380:475-83. [PMID: 22748821]
11. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004; 119:285-98. [PMID: 15479644]
12. Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol. 2005;32:252-5. [PMID: 15693084]
13. Kullo IJ, Hensrud DD, Allison TG. Comparison of numbers of circulating blood monocytes in men grouped by body mass index (<25, 25 to <30, > or = 30). Am J Cardiol. 2002;89:1441-3. [PMID: 12062747]
14. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353:1649-52. [PMID: 10335783]
15. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:455-61. [PMID: 11812755]
16. Friedman GD, Klatsky AL, Siegelaub AB. The leukocyte count as a predictor of myocardial infarction. N Engl J Med. 1974;290:1275-8. [PMID: 4827627]
17. Gillum RF, Mussolino ME, Madans JH. Counts of neutrophils, lymphocytes, and monocytes, cause-specific mortality and coronary heart disease: the NHANES-I epidemiologic follow-up study. Ann Epidemiol. 2005;15:266-71. [PMID: 15780773]
18. Grimm RH Jr, Neaton JD, Ludwig W. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA. 1985;254: 1932-7. [PMID: 4046122]
19. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956-9. [PMID: 8052854]
20. Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol. 1996;156:3961-9. [PMID: 8621937]
21. Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science. 1996;274: 1383-5. [PMID: 8910280]
22. Baichwal VR, Baeuerle PA. Activate NF-kappa B or die? Curr Biol. 1997; 7:R94-6. [PMID: 9081673]
23. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811-21. [PMID: 18946066]
24. Lafrance JP, Miller DR. Selective and non-selective non-steroidal antiinflammatory drugs and the risk of acute kidney injury. Pharmacoepidemiol Drug Saf. 2009;18:923-31. [PMID: 19585463]
25. Morris HG, Sherman NA, McQuain C, Goldlust MB, Chang SF, Harrison LI. Effects of salsalate (nonacetylated salicylate) and aspirin on serum prostaglandins in humans. Ther Drug Monit. 1985;7:435-8. [PMID: 3866409]
26. Ryan J. Effects of salsalate, aspirin and naproxen on plasma renin activity and platelet thromboxane synthesis. Arthritis Rheum. 1986;29(Suppl):S103.
27. Estes D, Kaplan K. Lack of platelet effect with the aspirin analog, salsalate. Arthritis Rheum. 1980;23:1303-7. [PMID: 7447965]
28. Sweeney JD, Hoernig LA. Hemostatic effects of salsalate in normal subjects and patients with hemophilia A. Thromb Res. 1991;61:23-7. [PMID: 2020937]
29. Sweeney JD. The effect of salsalate on bleeding time, platelet aggregation in whole blood and their release reaction. Blood. 1988;72(Suppl 1):311A.
30. Edmar D. Effects of salicylates on the gastric mucosa as revealed by roentgen examination and the gastrocamera. Acta Radiol Diagn (Stockh). 1971;11:57-64. [PMID: 4933979]
31. Roth S, Bennett R, Caldron P, Hartman R, Mitchell C, Doucette M, et al. Reduced risk of NSAID gastropathy (GI mucosal toxicity) with nonacetylated salicylate (salsalate): an endoscopic study. Semin Arthritis Rheum. 1990;19:11-9. [PMID: 2181673]
32. Lanza F, Rack MF, Doucette M, Ekholm B, Goldlust B, Wilson R. An endoscopic comparison of the gastroduodenal injury seen with salsalate and naproxen. J Rheumatol. 1989;16:1570-4. [PMID: 2625689]
33. Scheiman JM, Elta GH. Gastroduodenal mucosal damage with salsalate versus aspirin: results of experimental models and endoscopic studies in humans. Semin Arthritis Rheum. 1990;20:121-7. [PMID: 2123561]
34. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793-801. [PMID: 16823477]
35. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98-107. [PMID: 21233852]
36. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517-26. [PMID: 17429083]
37. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al; CANTOS Pilot Investigative Group. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012; 126:2739-48. [PMID: 23129601]
38. Smith MJ MJ, Bryant C, Hines WJ. Reversal by nicotinamide adenine dinucleotide of the inhibitory action of salicylate on mitochondrial malate dehydrogenase. Nature. 1964;202:96-7. [PMID: 14166735]
39. Hines WJ, Smith MJ. Inhibition of dehydrogenases by salicylate. Nature. 1964;201:192. [PMID: 14118278]
40. Aceves M, Dueñas A, Gómez C, San Vicente E, Crespo MS, Garci{dotless}́a-Rodri{dotless}́guez C. A new pharmacological effect of salicylates: inhibition of NFATdependent transcription. J Immunol. 2004;173:5721-9. [PMID: 15494524]
41. Jurivich DA, Sistonen L, Kroes RA, Morimoto RI. Effect of sodium salicylate on the human heat shock response. Science. 1992;255:1243-5. [PMID: 1546322]
42. Westerheide SD, Morimoto RI. Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem. 2005;280:33097-100. [PMID: 16076838]
43. Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J Biol Chem. 2003;278:24944-50. [PMID: 12714600]
44. Alpert D, Vilcek J. Inhibition of IkappaB kinase activity by sodium salicylate in vitro does not reflect its inhibitory mechanism in intact cells. J Biol Chem. 2000;275:10925-9. [PMID: 10753891]
45. Stevenson MA, Zhao MJ, Asea A, Coleman CN, Calderwood SK. Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclic AMP response element binding protein-and NF-kappa B-responsive genes. J Immunol. 1999;163:5608-16. [PMID: 10553090]
46. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396:77-80. [PMID: 9817203]
47. Schwenger P, Alpert D, Skolnik EY, Vilcek J. Activation of p38 mitogenactivated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation. Mol Cell Biol. 1998;18:78-84. [PMID: 9418855]
48. Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY, Vilcek J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci U S A. 1997;94:2869-73. [PMID: 9096313]
49. Frantz B, O'Neill EA. The effect of sodium salicylate and aspirin on NFkappa B [Letter]. Science. 1995;270:2017-9. [PMID: 8533099]
50. Nixon M, Wake DJ, Livingstone DE, Stimson RH, Esteves CL, Seckl JR, et al. Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization. Diabetes. 2012;61:790-6. [PMID: 22357964]
51. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 2012;336:918-22. [PMID: 22517326]
52. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31:289-94. [PMID: 17959861]
53. Koska J, Ortega E, Bunt JC, Gasser A, Impson J, Hanson RL, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia. 2009;52:385-93. [PMID: 19104769]